Table 3

Distribution of the study population and median overall survival according to the class of prognostic scores; Harrell’s concordance indexes (HCS)
Number of pts (%) MOS (95% CI) p Hazard Ratio (95% CI) HCS (95% CI)
RPA
1 26 (10.4) 25.6 M (18.4–32.9) 1 0.6783
2 166 (66.4) 10.4 M (8.9–12.6) <0.001 2.16 (1.34–3.50) (0.65–0.71)
3 58 (23.2) 2 M (1.4–3.1) 11.38 (6.57–19.70)
GPA
≥3 32 (12.8) 24.7 M (12.7–27.1) 1 0.658
1.5-2.5 116 (46.4) 12.3 M (10.1–15.1) <0.001 1.70 (1.09–2.65) (0.62–0.69)
0-1 102 (40.8) 4.2 M (3.1–5.4) 4.15 (2.62–6.55)
BS-BM
3 31 (12.4) 21.6 M (12.7–25.8) <0.001 1
2 68 (27.2) 12.7 M (9.7–18.4) 1.30 (0.81–2.08) 0.6803
1 96 (38.4) 8.7 M (6.1–12.3) 2.20 (1.41–3.46) (0.64–0.72)
0 55 (22.0) 2.2 M (1.4–3.6) 6.99 (4.25–11.47)
P1PS
0–1 95 (38.0) 16.4 M (11.9–23.3) 1 0.6251
2–3 64 (25.6) 5.9 M (3.4–8.4) <0.001 2.89 (2.01–4.14) (0.58–0.66)
Not available 91 (36.4)
Breast GPA
3.5-4 53 (21.2) 18.4 M (12.4–23.3) 1 0.6587
3 90 (36.0) 10.3 M (8.4–13.7) <0.001 1.37 (0.95–2.00) (0.62–0.69)
1.5-2.5 76 (30.4) 5.7 M (4–8) 2.09 (1.43–3.06)
0-1 31 (12.4) 2.3 M (1–4.1) 5.75 (3.56–9.27)
Breast RPA
1 20 (8.0) 21.3 M (9.7–53.9) 1 0.6037
2 192 (76.8) 9.8 M (8.4–12.1) <0.001 2.05 (1.20–3.50) (0.57–0.63)
3 38 (15.2) 2.3 M (1.8–4.3) 6.84 (3.69–12.72)
Le Scodan Score
1 89 (35.6) 15.2 M (11.5–19.4) 1 0.6239
2 49 (19.6) 9.7 M (7.5–12.4) <0.001 1.32 (0.91–1.92) (0.58–0.66)
3 112 (44.8) 4.2 M (3.3–6.1) 1.92 (1.43–2.59)

CI, Confidence Interval. MOS, Median Overall Survival (from brain metastases diagnosis). M, months. Pts, patients.

Braccini et al.

Braccini et al. BMC Cancer 2013 13:70   doi:10.1186/1471-2407-13-70

Open Data